NAFLD与肝细胞恶性转化相关研究新进展*

doi:10.3969/j.issn.1672-5069.2022.02.002

Abstract

Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.

[1] Huang DQ, El-Serag HB, Loomba R.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2021,18(4):223-238.
[2] Zou ZY, Zeng J, Ren TY, et al. Efficacy of intragastric balloons in the markers of metabolic dysfunction-associated fatty liver disease: Results from meta-analyses. J Clin Transl Hepatol, 2021, 9(3):353-363.
[3] Bence KK, Birnbaum MJ.Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab, 2021, 50:101143.
[4] Prasun P, Ginevic I, Oishi K.Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol, 2021,6:4.
[5] Choudhary NS, Duseja A.Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl Gastroenterol Hepatol, 2021, 6:2. DOI:10.21037/tgh.2019.09.06
[6] Geh D, Manas DM, Reeves HL.Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr, 2021, 10(1): 59-75.
[7] Eguchi Y, Wong G, Lee IH, et al.Hepatocellular carcinoma and other complications of non- alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works. Hepatol Res, 2021, 51(1):19-30.
[8] Feng G, Li XP, Niu CY, et al. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gene, 2020, 742: 144549.
[9] Jiang ZY, Zhou Y, Zhou L,et al. Identification of key genes and immune infiltrate in nonalcoholic steatohepatitis: A bioinformatic analysis. Biomed Res Int, 2021, 2021:7561645.
[10] Endo S, Matsunaga T, Nishinaka T.The role of AKR1B10 in physiology and patho- physiology. Metabolites, 2021,11(6):332.
[11] Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta- regression. Clin Gastroenterol Hepatol. 2021, S1542-3565(21)00505-X.
[12] Barrow F, Khan S, Wang H,et al. The emerging role of B cells in the pathogenesis of NAFLD. Hepatology, 2021[ahead of print].
[13] Khan O.Giles JR, McDonald S, et al. TOX transcriptionally and epigenetically programs CD8+T cell exhaustion. Nature, 2019,571:211–218.
[14] Pfister D, Núñez NG, Inyol R, et al. NASH limits anti-tumour surveillance in immuno-therapy-treated HCC. Nature, 2021,592(7854):450-456.
[15] Raza S, Rajak S, Upadhyay A, et al.Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed). 2021; 26:206-237.
[16] Ma C, Kesarwala AH, Eggert T, et al.NAFLD causes selective CD4 (+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016, 531(7593):253-257.
[17] Wang T, Sun G, Wang Y, et al.The immunoregulatory effects of CD8 T-cell-derived perforin on diet-induced nonalcoholic steatohepatitis. FASEB J, 2019, 33(7):8490-8503.
[18] Van Herck MA, Weyler J, Kwanten WJ, et al.The differential roles of T cells in non- alcoholic fatty liver disease and obesity. Front Immunol, 2019,10:82.
[19] Van Herck MA, Vonghia L, Kwanten WJ, et al.Adoptive cell transfer of regulatory T cells exacerbates hepatic steatosis in high-fat high-fructose diet-fed mice. Front Immunol, 2020, 11:1711.
[20] S＇widerska M, Jaroszewicz J, Stawicka A, et al. The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. Clin Exp Hepatol, 2017, 3(3):127-134.
[21] He B, Wu L, Xie W, et al.The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol, 2017,18(1):33.
[22] Durand M, Coué M, Croyal M, et al.Changes in key mitochondrial lipids accompany mito- chondrial dysfunction and oxidative stress in NAFLD. Oxid Med Cell Longev, 2021, 2021: 9986299.
[23] Dabravolski SA, Bezsonov EE, Baig MS, et al.Mitochondrial mutations and genetic factors determining NAFLD risk. Int J Mol Sci, 2021, 22(9):4459.
[24] Ajaz S, McPhail MJ, Gnudi L, et al.Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion 2021,57:119-130.
[25] Meex RCR, Blaak EE.Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD. Mol Nutr Food Res, 2021, 65(1): e1900942.
[26] Xiao WC, Ren M, Can Zhang C, et al. Amelioration of nonalcoholic fatty liver disease by hepatic stimulator substance via preservation of carnitine palmitoyl transferase-1 activity. Am J Physiol Cell Physiol, 2015, 309(4):C215-227.
[27] Gu JJ, Yao M, Yang J, et al.Mitochondrial carnitine palmitoyl transferase-II inactivity aggravates lipid accumulation in rat hepatocarcinogenesis. World J Gastroenterol, 2017, 23 (2): 256-264.
[28] Xu D, Tian Y, Xia Q, et al.The cGAS-STING pathway: Novel perspectives in liver diseases. Front Immunol, 2021, 12:682736.
[29] Li A, Yi M, Qin S, et al. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol, 2019,12: 35.
[30] Longo M, Paolini E, Meroni M, et al.Remodeling of mitochondrial plasticity: The key switch from NAFLD/NASH to HCC. Int J Mol Sci, 2021, 22(8):4173.
[31] Giraud J, Saleh M.Host-microbiota interactions in liver inflammation and cancer. Cancers (Basel), 2021,13(17):4342.
[32] Wu L, Li J, Feng J, et al.Crosstalk between PPARs and gut microbiota in NAFLD. Biomed Pharmacother, 2021, 136:111255.

Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[2]	Li Wei, Huang Yu, Zhong Jing, et al. Correlation of PNPLA3 rs738409 gene polymorphism to genetic susceptibility of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 227-230.
[3]	Jia Kun, Su Jianrong, Sun Wei. Clinical implication of LncRNA HEIH in serum and exosomes in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(6): 823-826.
[4]	Ma Shangji, Zheng Yang, Chen Xufeng, et al. Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease [J]. Journal of Practical Hepatology, 2021, 24(5): 705-708.
[5]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[6]	Liu Xiangji, Liu Zhenxian, Wang Xiaoyan. Incidence of gallstone disease in middle-aged and elderly patients with nonalcoholic fatty liver disease and its relation to metabolic risk factors [J]. Journal of Practical Hepatology, 2021, 24(3): 363-366.
[7]	Jin Ying, Zhou Weizhen, Feng Shibing, et al. Prevalence of nonalcoholic fatty liver diseases in patients with intracerebral hemorrhage [J]. Journal of Practical Hepatology, 2021, 24(3): 367-370.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Li Pingying, Li Juan, Xie Shouzhen, et al. Clinical application of FibroTouchand abdominal color ultrasound and computed tomography in diagnosis of individuals with nonalcoholic fatty liver disease in plateau regions [J]. Journal of Practical Hepatology, 2020, 23(6): 817-820.
[11]	Fang Yi, Chen Yixiong, Pei Dongping, et al.. Short-term efficacy of entecavir and lactobacillus acidophilus compound combination in the treatment of patients with chronic hepatitis B and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(5): 634-637.
[12]	Tang Xiaofei, Zhong Mengju, Shen Haijuan. Effect of naringenin Liposomes on lipid metabolism in nonalcoholic fatty liver disease rats [J]. Journal of Practical Hepatology, 2020, 23(3): 328-331.
[13]	Tang Xinya,Hou Sen,Jiao Yingying. Effect of captopril on steatosis of hepatocytes in rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(3): 332-335.
[14]	Shen Jingyong, Guo Xiangyun, Zhou Hui, et al. Effect of radical therapy forHelicobacter pylori on serum inflammatory factors and lipid metabolism in patients with Hp positive non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(3): 364-367.
[15]	Jiang Jiali, Li Li, Zhao Fei, et al. Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 167-170.